India · Delayed Price · Currency is INR Aptus Pharma Statistics
Total Valuation
Aptus Pharma has a market cap or net worth of INR 1.65 billion. The enterprise value is 1.59 billion.
| Market Cap | 1.65B |
| Enterprise Value | 1.59B |
Important Dates
The next estimated earnings date is Tuesday, February 10, 2026.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aptus Pharma has 6.86 million shares outstanding. The number of shares has increased by 861.92% in one year.
| Current Share Class | 6.86M |
| Shares Outstanding | 6.86M |
| Shares Change (YoY) | +861.92% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 72.89% |
| Owned by Institutions (%) | 6.38% |
| Float | 1.48M |
Valuation Ratios
The trailing PE ratio is 47.72.
| PE Ratio | 47.72 |
| Forward PE | n/a |
| PS Ratio | 5.65 |
| PB Ratio | 7.60 |
| P/TBV Ratio | 7.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 44.86 |
| EV / Sales | 5.44 |
| EV / EBITDA | 27.23 |
| EV / EBIT | 28.80 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.37.
| Current Ratio | 2.40 |
| Quick Ratio | 1.57 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 1.39 |
| Debt / FCF | n/a |
| Interest Coverage | 8.58 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 26.21% |
| Return on Capital Employed (ROCE) | 22.90% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 4.17M |
| Profits Per Employee | 505,857 |
| Employee Count | 70 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Aptus Pharma has paid 12.50 million in taxes.
| Income Tax | 12.50M |
| Effective Tax Rate | 26.09% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 175.17 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 83.07 |
| Average Volume (20 Days) | 38,400 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aptus Pharma had revenue of INR 291.80 million and earned 35.41 million in profits. Earnings per share was 5.04.
| Revenue | 291.80M |
| Gross Profit | 180.19M |
| Operating Income | 55.15M |
| Pretax Income | 47.91M |
| Net Income | 35.41M |
| EBITDA | 58.34M |
| EBIT | 55.15M |
| Earnings Per Share (EPS) | 5.04 |
Balance Sheet
The company has 142.82 million in cash and 81.35 million in debt, with a net cash position of 61.46 million or 8.96 per share.
| Cash & Cash Equivalents | 142.82M |
| Total Debt | 81.35M |
| Net Cash | 61.46M |
| Net Cash Per Share | 8.96 |
| Equity (Book Value) | 217.02M |
| Book Value Per Share | 42.97 |
| Working Capital | 216.87M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 61.75%, with operating and profit margins of 18.90% and 12.14%.
| Gross Margin | 61.75% |
| Operating Margin | 18.90% |
| Pretax Margin | 16.42% |
| Profit Margin | 12.14% |
| EBITDA Margin | 19.99% |
| EBIT Margin | 18.90% |
| FCF Margin | n/a |
Dividends & Yields
Aptus Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -861.92% |
| Shareholder Yield | -861.92% |
| Earnings Yield | 2.15% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |